Hycamtin and Neoplasm malignant - a phase IV clinical study of FDA data

Summary:

Neoplasm malignant is reported as a side effect among people who take Hycamtin (topotecan hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Neoplasm malignant when taking Hycamtin. It is created by eHealthMe based on reports of 2,349 people who have side effects when taking Hycamtin from the FDA, and is updated regularly.

What is Hycamtin?

Hycamtin has active ingredients of topotecan hydrochloride. eHealthMe is studying from 2,351 Hycamtin users. Check the latest studies of Hycamtin.

What is Neoplasm malignant?

Neoplasm malignant (cancer tumour) is found to be associated with 1,540 drugs and 1,261 conditions by eHealthMe. Check the latest studies of Neoplasm malignant.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

2,349 people reported to have side effects when taking Hycamtin.
Among them, 13 people (0.55%) have Neoplasm malignant.

Could Hycamtin cause Neoplasm malignant?

Among these 13 people:

How long have people been on Hycamtin when they have Neoplasm malignant? *

What is the gender of people who have Neoplasm malignant when taking Hycamtin? *

female: 53.85 %
male: 46.15 %

What is the age of people who have Neoplasm malignant when taking Hycamtin? *

What are other side effects people have besides Neoplasm malignant? *

Thrombocytopenia (decrease of platelets in blood): 2 people, 15.38%
Death: 2 people, 15.38%
White Blood Cell Count Decreased: 1 person, 7.69%
Memory Loss: 1 person, 7.69%
Malaise (a feeling of general discomfort or uneasiness): 1 person, 7.69%
Fatigue (feeling of tiredness): 1 person, 7.69%
Drug Ineffective: 1 person, 7.69%
Cough: 1 person, 7.69%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 7.69%
Anaemia (lack of blood): 1 person, 7.69%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 15.38%
Ovarian Cancer Stage Iv: 1 person, 7.69%
Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Hycamtin and have Neoplasm malignant?

- Check whether Neoplasm malignant is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Hycamtin:

Hycamtin (2,351 reports)

Browse all side effects of Hycamtin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm malignant:

Neoplasm malignant (1,540 drugs)

Browse all the conditions that are associated with Neoplasm malignant:

Neoplasm malignant (1,261 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on topotecan hydrochloride (the active ingredients of Hycamtin) and Hycamtin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.